Abstract
Glutaredoxin from the cyanobacterium Synechocystis sp. PCC 6803 is a small protein, containing only 88 amino acids, that participates in a large number of redox reactions, serving both as an electron donor for enzyme-catalyzed reductions and as a regulator of diverse metabolic pathways. The crystal structures of glutaredoxins from several species have been solved, including the glutaredoxin A isoform from the cyanobacterium Synechocystis sp. PCC 6803. We have utilized the small size of Synechocystis glutaredoxin A and its propensity to form protein crystals that diffract to high resolution to explore a long-standing question in biochemistry; i.e., what are the effects of mutations on protein structure and function? Taking advantage of these properties, we have initiated a long-term educational project that would examine the structural and biochemical changes in glutaredoxin as a function of single-point mutational replacements. Here, we report some of the mutational effects that we have observed to date.
Introduction
Glutaredoxin, a member of the glutaredoxin/thioredoxin superfamily, was originally discovered during the search for the electron donor for Escherichia coli ribonucleotide reductase (Holmgren, , ). Later, it was determined that glutaredoxins serve not only as the electron donor for a variety of reductant-requiring enzymes, but also as essential components in other cellular processes. For example, glutaredoxins play a critical role in restoring protein function following damage by oxidative stress, as well as mediating the response to heavy metal ion induced damage (Lundstrom-Ljung and Holmgren, ). Plant glutaredoxins play strategic roles in signaling pathways, as they participate in the regulation of diverse metabolic pathways. They are also involved in the regulation of gene expression (Couturier et al., ). In the case of the glutaredoxin that is the focus of this study, glutaredoxin A from the cyanobacterium Synechocystis sp. PCC 6803 serves as the preferred electron donor for the 2-electron reduction of arsenate to arsenite, catalyzed by arsenate reductase (Li et al., ; Lopez-Maury et al., ).
As part of the thioredoxin superfamily, glutaredoxin A shares the characteristic thioredoxin fold. This motif is most prominent in prokaryotic glutaredoxins, including glutaredoxin A from Synechocystis sp. PCC 6803, while the thioredoxin fold only exists as a substructure or domain in eukaryotic glutaredoxins (Figure 1) (Eklund et al., ). The small size, the ease of purification, and the physiological importance of this protein in both prokaryotes and eukaryotes make Synechocystis sp. PCC 6803 glutaredoxin A an ideal platform on which to base the study of protein mutations.
Figure 1
We previously reported the high-resolution crystal structure of glutaredoxin A from Synechocystis sp. PCC 6803 (Figure 2) (Kim et al.,
Figure 2

Structure of wild-type glutaredoxin from Synechocystis sp. PCC 6803. Magenta arrows correspond to β-strands; cyan coils represent α-helices. Sulfate anions are shown in the space filling representation. Also shown as sticks, are the six histidine residues used for affinity purification. The amino (N) and carboxy (C) termini are labeled.
Another marked difference between the Synechocystis sp. PCC 6803 glutaredoxin A structure and other glutaredoxin structures is the lack of a disulfide bond between the two cysteine residues at the catalytically-active site, i.e., Cys15 and Cys18. The oxidation-reduction midpoint potential of the active site disulfide/dithiol couple in Synechocystis glutaredoxin A has been measured at −225 mV at pH 7.0 (Kim et al.,
Site-directed mutagenesis has been used for many years to investigate the detailed function of genes and proteins (Muller et al.,
Results and discussion
Widespread mutagenesis studies have previously been carried out with proteins other than glutaredoxins. For example, extensive analysis of the T4 lysozyme protein using a rational selection of sites, uncovered valuable information on the biophysics of protein folding and stability (Baase et al.,
Effects of randomly selected mutations
Given that our mutations are randomly selected, at least four possible outcomes are expected. First, the mutated gene yields a protein that is unable to fold, and thus, would exhibit very low solubility. In this case, the protein could be sequestered in inclusion bodies in the bacteria, it could be completely proteolyzed, or it would yield only extremely low amounts of soluble protein. Second, the protein may be soluble, but is unable to crystallize under our current crystallization conditions. Third, the protein may crystallize, but the resulting crystals are too small for rapid analysis. Fourth, large, single-protein crystals are formed, and are amenable for crystallographic analysis.
We assume that many of the randomly selected mutations in the glutaredoxin gene will result in protein misfolding. For example, mutations within the hydrophobic core of most proteins are not well tolerated (Guo et al.,
Mutants of glutaredoxin a that produce protein crystals
Four of our mutant proteins produced crystals suitable for X-ray structure determination (Tables 1, 2). At least 10 of the 28 mutations that we have examined have produced crystalline material (Table 1). We define “crystalline material” as protein crystals that form either thin, fibrous crystals or protein crystals that are too small to justify further effort. Proteins that form fibrous crystals typically add protein molecules to the crystal lattice preferentially along one growth axis. In our case, A2I, A2T, I9L, R27V, K28C, A43I, A43T, A49H, A49W, and R55A variants each produced sub-optimal protein crystals. Interestingly, both hydrophobic and polar variants replacing Ala2 (A2I, A2T, and A2Y) produced soluble protein, but only A2I and A2T grew protein crystals, albeit crystals of poor quality. This particular locus on the molecule is in a flexible loop at the beginning of the polypeptide chain and is not involved in any direct crystal contacts; however, there are residues from symmetry-related molecules within 5 Å of this locus. The introduction of a bulky mutation such as Tyr could add as many as 6 new amino acid neighbors within a 5 Å sphere that could interfere with crystal packing (Table 1).
Table 1
| Mutation | Soluble | Insoluble | Crystallize | Δ #Neighbors | Pseudo ΔΔG kcal/mol|prediction | Final structure | |
|---|---|---|---|---|---|---|---|
| WT | ✓ | ✓ | – | – | Yes | ||
| A2Y | ✓ | – | +6 | −0.02 | n | ||
| A2I | ✓ | ✓ | +1 | −0.30 | n | ||
| A2T | ✓ | ✓ | +1 | −0.6 | sd | ||
| I9L | ✓ | ✓ | 0 | −0.59 | sd | ||
| T11Y | X | ✓ | – | +3 | +1.39 | s | |
| F17N | ✓ | – | −4 | −1.89 | d | ||
| M19A | ✓ | – | −2 | +0.91 | ss | ||
| A23N | ✓ | – | 0 | −3.62 | hd | ||
| L25S | X | ✓ | – | −3 | −4.56 | hd | |
| R27L | ✓ | ✓ | −2 | −0.08 | n | Yes | |
| R27V | ✓ | ✓ | −1 | −0.82 | sd | ||
| K28C | ✓ | ✓ | −1 | +0.56 | ss | ||
| G29C | ✓ | – | +2 | −0.44 | n | ||
| E34L | ✓ | – | 0 | +1.00 | ss | ||
| A43G | ✓ | – | −1 | −3.54 | hd | ||
| A43I | ✓ | ✓ | +2 | +0.27 | n | ||
| A43T | ✓ | ✓ | +3 | −2.29 | hd | ||
| A49H | ✓ | ✓ | +2 | −2.10 | hd | ||
| A49W | ✓ | ✓ | +4 | −2.32 | hd | ||
| A51E | ✓ | – | +4 | −2.84 | hd | ||
| R55A | ✓ | ✓ | −4 | +0.11 | n | ||
| G68Y | X | ✓ | – | +1 | +3.18 | hs | |
| G69F | ✓ | – | +3 | +1.83 | s | ||
| C70S | ✓ | – | 0 | −3.69 | hd | ||
| A75I | ✓ | ✓ | 0 | −1.19 | d | Yes | |
| A79S | ✓ | ✓ | 0 | −0.58 | ds | Yes | |
| P84R | ✓ | ✓ | +3 | +1.65 | s | Yes | |
List of currently studied mutations in Synechocystis sp. PCC 6803 glutaredoxin A.
Soluble = mutant protein could be purified from bacterial lysate.
Insoluble = no mutant protein could be purified from bacterial lysate.
Crystallize = were crystals of any quality grown?
Δ #Neighbors = residues which could cause potential collisions in this crystallographic setting.
Pseudo ΔΔG (kcal/mol) n, neutral; sd, slightly destabilizing; s, stabilizing; d, destabilizing; hd, highly destabilizing; ss, slightly stabilizing; hs, highly stabilizing.
Structure = Was a refined crystal structure produced?
Table 2
| PDB code: | R27L | A75I | A79S | P84R |
|---|---|---|---|---|
| 4MJE | 4MJA | 4MJB | 4MJC | |
| DATA COLLECTION | ||||
| Wavelength (Å) | 0.9795 | 1.2320 | 1.2830 | 1.1270 |
| Space group | P212121 | P212121 | P212121 | P212121 |
| CELL DIMENSIONS | ||||
| a, b, c (Å) | 37.3, 39.1, 50.6 | 37.2, 38.4, 51.6 | 37.2, 38.1, 51.6 | 37.2, 38.8, 50.7 |
| α, β, γ (°) | 90, 90, 90 | 90, 90, 90 | 90, 90, 90 | 90, 90, 90 |
| Resolution (Å) | 30.95-1.2 | 30.81-2.0 | 30.68-2.1 | 30.83-1.4 |
| Mosaicity (°) | 0.35 | 0.67 | 0.4 | 0.79 |
| Rsym or Rmerge | 7.4 (30.4) | 7.3 (19.2) | 4.5 (13.1) | 6.7 (31.9) |
| I/σ I | 11.8 (3.3) | 16 (7.0) | 20.2 (2.2) | 9.6 (3.2) |
| Completeness (%) | 99.5 (99.8) | 99.9 (99.7) | 99.3 (87.5) | 98.8 (99.8) |
| Redundancy | 13.3 (13.2) | 6.3 (6.4) | 6.8 (6.6) | 3.3 (3.3) |
| REFINEMENT | ||||
| Resolution (Å) | 30-1.2* | 30-2.0** | 30.7-2.11 | 26.8-1.4 |
| No. reflections | 23433 | 5603 | 4418 | 14533 |
| Rwork/Rfree (%) | 17.87/19.78 | 20.57/22.92 | 19.02/22.81 | 17.81/21.57 |
| NO. ATOMS | ||||
| Protein | 1654 | 846 | 838 | 883 |
| SO4 | 10 | – | 10 | 5 |
| Water | 106 | 62 | 51 | 93 |
| B-FACTORS (Å2) | ||||
| protein | 9.8 | 20.50 | 22.60 | 15.8 |
| SO4 | 20.0 | – | 99.60 | 16.8 |
| Water | 20.0 | 26.40 | 26.90 | 24.1 |
| R.M.S. DEVIATIONS | ||||
| Bond lengths (Å) | 0.009 | 0.03 | 0.004 | 0.009 |
| Bond angles (°) | 1.27 | 2.13 | 0.96 | 1.298 |
| RAMACHANDRAN PLOT | ||||
| % Ideal | 97 | 94 | 95 | 97 |
| % Allowed | 3 | 6 | 5 | 3 |
| Outliers | 0 | 0 | 0 | 0 |
Data collection and refinement statistics.
Coordinates refined with “riding” hydrogen atoms.
No sulfate ions were present in this crystal structure.
The I9L replacement should be a conservative change in the protein, as the physio-chemical properties and side chain volumes of isoleucine and leucine are very similar. Mutational studies of other proteins have concluded that these two amino acids are largely interchangeable and that replacement of one by the other generally has little or no effect on a protein's biophysical properties (Betts and Russell,
Four new mutant structures
Our random mutagenesis approach has yielded four new crystal structures of glutaredoxin A, one for each of the following variants: R27L, A75I, A79S, and P84R (Table 2). Each of these crystal structures provides information about the structure and function of the glutaredoxin protein, in addition to information about protein crystal formation and protein structure in general.
The overall structure of the R27L variant is virtually indistinguishable from that of the wild-type protein. The RMSD (root-mean-square deviation) between both structures is 0.099 Å over all atoms, and the Leu27 substitution was confirmed in the refined experimental electron density (Figure 3). Arg27 occurs at the C-terminal end of α-helix 1 of the wild-type protein and potentially forms a H-bond with Tyr74. In addition, Arg27 occurs in a cluster of other basic residues (...K-R-K...), so it is likely that it is part of a localized positively charged patch on the surface of the protein. The leucine substitution would obviously disrupt this patch, but little else would be predicted to occur. Nevertheless, the diffraction resolution of the crystals of the R27L variant was significantly increased compared to the data obtained with wild-type glutaredoxin A. Diffraction resolution is an optical property of crystals, which is dictated by the inherent order of a crystal lattice to diffract X-rays. The lower the value for the resolution, the better the crystal is ordered and the better it can provide X-ray diffraction data that can resolve the measured distance between atoms. Crystals of the wild-type protein diffract to 1.7 Å resolution, while the R27L mutation produced crystals that diffract X-rays to 1.2 Å resolution. The sizes of the crystals of the wild-type and R27L variants were similar, so the increase in diffraction cannot be explained by larger crystals. Furthermore, as all data were collected at the same X-ray source, increased X-ray intensity cannot explain this increase in resolution. Therefore, it is likely that a property of the mutation contributed to this effect. There is a possibility that more efficient hydrophobic packing between symmetry-related molecules, mediated by the leucine replacement, contributed to more efficient crystal packing. This observation is essentially what has been described as surface entropy reduction (SER). SER is an in silico technique that predicts mutants, which could possibly facilitate more productive contacts among protein molecules in a crystal lattice (Goldschmidt et al.,
Figure 3

Representative 2Fo-Fc electron density maps, contored at the 1σ level, of each of the four mutations described. (A) A75I: The wild-type Ala is shown as light blue ball-and-stick, while the mutant Ile is shown as green sticks. The chicken wire shape around the amino acid represents the electron density carved from the final refined structure. (B) A79S: Ala79 is shown as blue balls-and-sticks. The mutant Ser is shown as green sticks. In this case, two conformations of Ser79 can be modeled. Both rotamers were used at 50% occupancy in the refinement of this structure. (C) P84R: wild-type Pro 84 is shown as blue balls-and-sticks. Mutant Arg79 is shown as green sticks. It is common for the more flexible amino acids, such as Arg or Lys, to exhibit abbreviated electron density due to the rotary motion of the side chain. (D) R27L: The Arg27 present in the wild-type protein is shown as blue balls-and-sticks. The structure of the leucine replacement at this position has been superimposed on top of the wild-type and is shown as green sticks.
Due to the location of Ala75, one might have predicted that changes in structure and function observed for the A75I and the A79S variants would be subtle. These replacements are located at the extreme C-terminus of the protein in α-helix 4 (Figure 2), and both are exposed to the outside surface of the helix. Neither is involved in crystal packing interactions nor core packing interactions, and therefore, these positions are predicted to be highly tolerant of modification. However, in the case of the A79S mutant, there are minor structural changes observed in the geometry of α-helix 4. There is a measurable decrease in the twist of the helix, a decrease in the helix-bending angle of α-helix 4 (Table 3). The significance of these minor changes remains to be explored.
Table 3
| Mutation | Twist (°) | n | height (Å) | Bending angle (°) |
|---|---|---|---|---|
| Wild-type | 102.2 | 3.52 | 1.67 | 7.3 |
| R27L | 101.1 | 3.56 | 1.76 | 7.8 |
| A75I | 101.1 | 3.60 | 1.65 | 7.6 |
| A79S | 101.3 | 3.55 | 1.68 | 5.4 |
| P84R | 101.8 | 3.54 | 1.66 | 11.8 |
Changes in helix properties in helix α-4 of glutaredoxin (Bansal et al.,
n = amino acids/turn.
h (Å) = unit height of the helix.
Bending angle (°) = Bending angle between successive local helix axes.
The P84R mutation is interesting from a structural perspective. Firstly, Pro84 occurs at the beginning of an α-helix that is bent by almost 90° relative to a neighboring α-helix in the structure. The only impetus for this dramatic bend is the maintenance of a protected hydrophobic core. A proline is present at this locus in other glutaredoxin molecules, but not all. A Blast search using the Synechocystis sp. PCC 6803 glutaredoxin A sequence revealed that 48% of 98 glutaredoxin sequences utilize proline at a homologous position in the primary sequence (data not shown). As proline does not provide a free backbone amide hydrogen to form an H-bond to the i + 4 backbone carbonyl, it rarely occurs within a helix (Kim and Kang,
Figure 4

Superposition of helix α-4 from Glutaredoxin A. The green structure is wild-type, while the blue structure is mutant P84R. The dashed-lines are backbone H-bonds that stabilize α-helix 4. One additional consensus H-bond has been included in the P84R structure.
Changes in protein stability
Many of the mutations that we introduce using our random selection method could compromise protein stability in many different ways. For example, secondary structure may be disrupted by introducing a residue incompatible with β-sheet formation. The resulting misfolded protein could result in an insoluble protein in E. coli. To predict changes in stability, we submitted our point mutants to the Site Directed Mutator (SDM) server for analysis (Table 1). This procedure returns a prediction on whether the point mutation is neutral, stabilizing, or destabilizing based on environment-specific substitution tables and the resulting change in free energy (Worth et al.,
Inconsistencies with the orthorhombic crystal lattice
Ideally, we would like to screen each soluble, purified glutaredoxin A mutation for its own unique crystallization condition, but we are limited in resources and by the time our students can spend with this research project. Therefore, we have concentrated on a single crystallographic condition. This restriction obviously imposes limitations on our method, but it also addresses the question about how variable or plastic a protein can be yet pack into a given lattice. Most of our mutants form suboptimal protein crystals. It is possible that the modifications we make to the glutaredoxin protein produces changes that cannot form productive crystal contacts, and therefore, disfavors efficient crystal packing. To assess this, we studied the change in the number of neighboring inter-molecular residues (within 5 Å) between mutant and wild-type glutaredoxin, assuming orthorhombic crystal packing (Table 1). More inter-molecular neighbors would likely correlate with potential clashes; whereas, fewer contacts could correlate with missing interactions. One would predict that extremes in both would make the protein less likely to crystallize in the orthorhombic setting we have measured in the wild-type glutaredoxin. Interestingly, in the case of the mutations that produced crystal structures, there is no obvious correlation between either adding or subtracting inter-molecular neighbors. The R27L crystal structure lacks two neighbors; the A75I and A79S mutant have no net differences, while the P84R mutant adds three possible interactions (Table 1). This result could reflect the plastic nature of proteins that allows them to adopt new shapes. As we have also observed that most of our soluble glutaredoxin mutants can form crystalline material, it is therefore, possible that changing the number of clashes either could make nucleation more probable or alternatively, could hinder crystal growth. As our dataset increases in size with time, we will be able to make more definitive conclusions.
Sulfate binding
Since ammonium sulfate is used in the crystallization medium of these glutaredoxin A crystals, there are two sulfate anions coordinated to the wild-type and to the mutated glutaredoxin A structures. Interestingly, the A75I mutation does not coordinate sulfate ions in its crystal structure. In the wild-type structure, sulfate #2 (Figure 2) is 10.6 Å from the Cα atom of Ile75, while sulfate #1 (Figure 2) is 35.2 Å distant. The large distance between the site of the mutation and the ligand binding site discounts any direct effect on sulfate binding. A cogent rationale for the absence of sulfate anions in the electron density is still unknown; however, we can draw conclusions about the effects of sulfate binding to the A75I crystal structure. As there is no sulfate anion bound to the N-terminus, the His-tag of A75I is considerably more disordered that the other glutaredoxin structures that do coordinate sulfate. The temperature factor is a measure of thermal motion within a crystal structure; atoms with higher temperature factors are thought to be more disordered. The average refined temperature-factors for the artificial N-terminus of wild-type glutaredoxin A (the loop including the His-tag residues) including the coordinated sulfate anion is 17.7 Å2. The same residues in the A75I structure without a coordinated sulfate anion show an average temperature factor of 32.6 Å2 (Figure 5). While the elevated temperature factors can be explained by the lack of sulfate coordination, the rationale for the lack of this anion in this mutation is still unknown.
Figure 5

Superimposed Temperature Factor plot of wild-type glutaredoxin (solid circles) (3QMX) vs. A75I (white circles). The red color depicts the His-residues that make up the His-tag of the molecule. The arrows show the location of the shortest sulfate:amino acid distance.
Conclusion
Our random point mutant selection scheme will ultimately cover all of the 1672 possible mutations of Synechocystis sp. PCC 6803 glutaredoxin A, while simultaneously teaching students about biotechnology and protein structure. There are, however, several weaknesses to this method. Due to time constraints, we have to restrict our crystallization experiments to one specific condition; one that had originally been identified during crystallization trials for the wild-type protein. While we will clearly learn how mutation affects crystal growth under these conditions, a broader-ranging, independent approach would be more informative. Another weakness of this project is that we seek to involve students from different institutions with a wide range of backgrounds and training. As such, it introduces considerable variability in the skill with which different amino acid replacements will be carried out and analyzed. While only the most diligent students will be able to make significant headway in this project, the rewards of involving a large number of students and potentially exciting them about science surely outweighs the negative aspects.
It is hoped that we will ultimately compile an extensive database that will include information to stabilize protein folds or, perhaps, to reveal techniques that improve protein crystal diffraction. However, in the limited coverage of mutational space that we have already explored, it is clear that not all mutations can be immediately understood, and their effects are still reasonably unpredictable. This is one of the primary concepts that we try to instill in students from the beginning.
Materials and methods
Heterologous expression
The mutagenesis protocol that we use is described in detail (Kim et al.,
1.0 μg of plasmid DNA was added to 100 μ l of chemically competent BL-21(DE3) E. coli in a 1.5 ml microfuge tube. This mixture was incubated on ice for 30 min. The cells were then heat-shocked at 37°C in a water-bath for 45 s. 650 μl of SOC medium were added to each microfuge tube. The plasmid DNA/BL-21(DE3) mixture and the SOC medium were placed in a 37°C incubator, shaken at 225 r.p.m. for a 1 h and subsequently plated onto an agar substrate containing 100 μ g ml 87,221 ampicillin. The plates were then placed in a stationary incubator at 37°C for 12 h. Start-up cultures were prepared by inoculating individual colonies from the plasmid transformation plate into 25 mL of Luria-Bertani medium (LB) and 100 μg ml−1 of ampicillin. This culture was incubated at 37°C while shaking at 225 r.p.m. overnight. The start-up LB cultures were added to 1 L Terrific broth (TB) to maximize bacterial cell yield. TB cultures were incubated at 37°C, with shaking at 225 r.p.m. until OD600 reached 1.3, at which point 400 μl of isopropyl β-D-1-thiogalactopyranoside (IPTG) was introduced to induce protein expression. Prior to IPTG induction, a 500 μ l sample of un-induced cells was set aside for PAGE electrophoresis. TB cultures were incubated for a 12 h period at 20°C for a 3–4 h period at 37°C, with shaking at 225 r.p.m. and subsequently spun down at 7200 r.p.m. in a centrifuge at 4°C. A post-induction gel electrophoresis sample was taken prior to centrifugation to confirm heterologous expression. Cell pellets were collected, flash-frozen in liquid nitrogen, and stored at −80°C until lysis.
Purification
Following SDS-PAGE verification of heterologous protein induction in bacteria, cell cultures were thawed at 0°C, suspended in a lysis buffer (30 mM Tris buffer, pH 8.0, containing 500 mM NaCl), vortexed, and then lysed at 20,000 psi in a Microfluidics M-100EH microfluidizer. Lysed cells were centrifuged at 42,000 r.p.m. for 45 min at 4°C; the supernatant was subsequently collected and bound to Ni-NTA resin for 12 h. Glutaredoxin-bound Ni-NTA resin was washed with 30 mM Tris buffer, pH 8.0, containing 500 mM NaCl plus 30 mM imidazole until the OD280of the eluent was ≤0.010. Glutaredoxin A was eluted from the column with 40–50 ml of 30 mM Tris buffer, pH 8.0, containing 300 mM imidazole, plus 500 mM NaCl. Post-elution protein purity was confirmed by SDS-PAGE using a Phastgel apparatus (GE Healthcare). Protein concentrations were determined either using the BioRad Protein Assay with bovine serum albumin as a standard (Bradford,
Crystallization
Crystallization trials of all mutant glutaredoxin proteins utilized the hanging-drop vapor-diffusion method. Noting previously identified glutaredoxin A wild-type crystallization conditions, 24 well trays were set up with a horizontally varying salt gradient (1.1–1.5 M ammonium sulfate), and a vertically varying pH gradient (pH 7.0–8.2 HEPES buffer). 1% PEG400 (w/v) was included throughout. Crystal droplets consisting of 2 μl protein solution and 2 μl reservoir solution were added and trays were placed in 23°C for crystallization. Long, rod-like structures displaying the typical morphology of glutaredoxin crystals generally appeared after 24 h; however, some mutants grew crystals in as much as 2 weeks.
Structure solution
The crystals were captured on nylon loops and flash frozen in liquid N2. Initial data sets were collected on a Rigaku ScreenMachine. Subsequent data sets were collected at SLAC beamline 7-1. The data were collected at 90 K. X-ray data was processed with imosflm (Battye et al.,
Structures of all mutants were solved by molecular replacement using 3QMX as the target structure. We used the Phaser module as implemented in the Phenix package for this calculation. Subsequent electron density for the protein was manually fit using Coot (Emsley et al.,
Mutant analysis
The thermodynamic stability for each single site mutant in our data set was predicted using the SDM web server (Worth et al.,
Potential conflicts with the wild-type crystal packing were analyzed in Pymol (Schrodinger,
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Statements
Acknowledgments
This work was supported by a grant from the CH Foundation (to Roger B. Sutton) and the U.S. Department of Energy (DE-FG03-99ER20346 to David B. Knaff). These two funding sources contributed equally to supporting the project. Portions of this research were carried out at the Stanford Synchrotron Radiation Lightsource, a Directorate of SLAC National Accelerator Laboratory and an Office of Science User Facility operated for the U.S. Department of Energy Office of Science by Stanford University. The SSRL Structural Molecular Biology Program is supported by the DOE Office of Biological and Environmental Research, and by the National Institutes of Health, National Institute of General Medical Sciences (including P41 GM103393) and the National Center for Research Resources (P41 RR001209). The contents of this publication are solely the responsibility of the authors and do not necessarily represent the official views of NIGMS, NCRR or NIH. The authors would like to acknowledge the assistance of Dr. Jatindra N. Tripathy (Center for Biotechnology and Genomics, Texas Tech University) in helping to supervise the course (BTEC 5338) at Texas Tech University where the mutational study was initiated. In addition, the authors would like to thank students from Wayland Baptist University, Eastern New Mexico University, Southern Illinois University Edwardsville, The Air Force Academy, and Baylor University for contributing. All structures and structure factors have been deposited with the PDB under the following accession codes: wild-type glutaredoxin (3QMX), glutaredoxin A-A75I (4MJA), glutaredoxin A-A79S (4MJB), glutaredoxin A-P84R (4MJC), glutaredoxin A-R27L (4MJE).
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1
AdamsP. D.AfonineP. V.BunkocziG.ChenV. B.DavisI. W.EcholsN.et al. (2010). PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 66, 213–221. 10.1107/S0907444909052925
2
BaaseW. A.LiuL.TronrudD. E.MatthewsB. W. (2010). Lessons from the lysozyme of phage T4. Protein Sci. 19, 631–641. 10.1002/pro.344
3
BansalM.KumarS.VelavanR. (2000). HELANAL: a program to characterize helix geometry in proteins. J. Biomol. Struct. Dyn. 17, 811–819. 10.1080/07391102.2000.10506570
4
BattyeT. G.KontogiannisL.JohnsonO.PowellH. R.LeslieA. G. (2011). iMOSFLM: a new graphical interface for diffraction-image processing with MOSFLM. Acta Crystallogr. D Biol. Crystallogr. 67, 271–281. 10.1107/S0907444910048675
5
BettsM. J.RussellR. B. (2003). Amino acid properties and consequences of substitutions, in Bioinformatics for Geneticists, eds GrayI. C.BarnesM. R. (Southern Gate Chichester, UK: John Wiley & Sons, Ltd.), 289–314.
6
BradfordM. M. (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248–254.
7
BrautigamL.JohanssonC.KubschB.McDonoughM. A.BillE.HolmgrenA.et al. (2013). An unusual mode of iron-sulfur-cluster coordination in a teleost glutaredoxin. Biochem. Biophys. Res. Commun. 436, 491–496. 10.1016/j.bbrc.2013.05.132
8
CouturierJ.ChibaniK.JacquotJ. P.RouhierN. (2013). Cysteine-based redox regulation and signaling in plants. Front. Plant Sci. 4:105. 10.3389/fpls.2013.00105
9
CouturierJ.KohC. S.ZaffagniniM.WingerA. M.GualbertoJ. M.CorbierC.et al. (2009). Structure-function relationship of the chloroplastic glutaredoxin S12 with an atypical WCSYS active site. J. Biol. Chem. 284, 9299–9310. 10.1074/jbc.M807998200
10
DobrovolskaO.ShumilinaE.GladyshevV. N.DikiyA. (2012). Structural analysis of glutaredoxin domain of Mus musculus thioredoxin glutathione reductase. PLoS ONE7:e52914. 10.1371/journal.pone.0052914
11
EklundH.CambillauC.SjobergB. M.HolmgrenA.JornvallH.HoogJ. O.et al. (1984). Conformational and functional similarities between glutaredoxin and thioredoxins. EMBO J. 3, 1443–1449.
12
EmsleyP.LohkampB.ScottW. G.CowtanK. (2010). Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486–501. 10.1107/S0907444910007493
13
FladvadM.BellandaM.FernandesA. P.MammiS.Vlamis-GardikasA.HolmgrenA.et al. (2005). Molecular mapping of functionalities in the solution structure of reduced Grx4, a monothiol glutaredoxin from Escherichia coli. J. Biol. Chem. 280, 24553–24561. 10.1074/jbc.M500679200
14
GillS. C.Von HippelP. H. (1989). Calculation of protein extinction coefficients from amino acid sequence data. Anal. Biochem. 182, 319–326. 10.1016/0003-2697(89)90602-7
15
GoldschmidtL.CooperD. R.DerewendaZ. S.EisenbergD. (2007). Toward rational protein crystallization: a Web server for the design of crystallizable protein variants. Protein Sci. 16, 1569–1576. 10.1110/ps.072914007
16
GuoH. H.ChoeJ.LoebL. A. (2004). Protein tolerance to random amino acid change. Proc. Natl. Acad. Sci. U.S.A. 101, 9205–9210. 10.1073/pnas.0403255101
17
HolmgrenA. (1976). Hydrogen donor system for Escherichia coli ribonucleoside-diphosphate reductase dependent upon glutathione. Proc. Natl. Acad. Sci. U.S.A. 73, 2275–2279. 10.1073/pnas.73.7.2275
18
HolmgrenA. (1979). Glutathione-dependent synthesis of deoxyribonucleotides. Purification and characterization of glutaredoxin fromEscherichia coli. J. Biol. Chem. 254, 3664–3671.
19
KimM. K.KangY. K. (1999). Positional preference of proline in alpha-helices. Protein Sci. 8, 1492–1499. 10.1110/ps.8.7.1492
20
KimS. G.ChungJ. S.SuttonR. B.LeeJ. S.Lopez-MauryL.LeeS. Y.et al. (2012). Redox, mutagenic and structural studies of the glutaredoxin/arsenate reductase couple from the cyanobacterium Synechocystis sp. PCC 6803. Biochim. Biophys. Acta1824, 392–403. 10.1016/j.bbapap.2011.11.012
21
KumarP.BansalM. (2012). HELANAL-Plus: a web server for analysis of helix geometry in protein structures. J. Biomol. Struct. Dyn. 30, 773–783. 10.1080/07391102.2012.689705
22
LiR.HaileJ. D.KennellyP. J. (2003). An arsenate reductase from Synechocystis sp. strain PCC 6803 exhibits a novel combination of catalytic characteristics. J. Bacteriol. 185, 6780–6789. 10.1128/JB.185.23.6780-6789.2003
23
Lopez-MauryL.FlorencioF. J.ReyesJ. C. (2003). Arsenic sensing and resistance system in the cyanobacterium Synechocystis sp. strain PCC 6803. J. Bacteriol. 185, 5363–5371. 10.1128/JB.185.18.5363-5371.2003
24
Lundstrom-LjungJ.HolmgrenA. (1995). Glutaredoxin accelerates glutathione-dependent folding of reduced ribonuclease A together with protein disulfide-isomerase. J. Biol. Chem. 270, 7822–7828. 10.1074/jbc.270.14.7822
25
MullerW.WeberH.MeyerF.WeissmannC. (1978). Site-directed mutagenesis in DNA: generation of point mutations in cloned beta globin complementary dna at the positions corresponding to amino acids 121 to 123. J. Mol. Biol. 124, 343–358. 10.1016/0022-2836(78)90303-0
26
Schrodinger, LLC. (2013). The PyMOL Molecular Graphics System, Version 1.6.
27
WinnM. D.BallardC. C.CowtanK. D.DodsonE. J.EmsleyP.EvansP. R.et al. (2011). Overview of the CCP4 suite and current developments. Acta Crystallogr. D Biol. Crystallogr. 67, 235–242. 10.1107/S0907444910045749
28
WorthC. L.PreissnerR.BlundellT. L. (2011). SDM–a server for predicting effects of mutations on protein stability and malfunction. Nucleic Acids Res. 39, W215–W222. 10.1093/nar/gkr363
Summary
Keywords
glutaredoxin A, educational platform, mutagenesis, protein structure, tertiary, synechocystis sp. PCC 6803
Citation
Knaff DB and Sutton RB (2013) Utility of Synechocystis sp. PCC 6803 glutaredoxin A as a platform to study high-resolution mutagenesis of proteins. Front. Plant Sci. 4:461. doi: 10.3389/fpls.2013.00461
Received
28 August 2013
Accepted
26 October 2013
Published
15 November 2013
Volume
4 - 2013
Edited by
Jose A. Traverso, Consejo Superior de Investigaciones Científicas, Spain
Reviewed by
Nathan Nelson, Tel-Aviv University, Israel; Xiaoqiang Wang, Samuel Roberts Noble Foundation, USA; Javier Lopez-Jaramillo, Universidad de Granada, Spain
Copyright
© 2013 Knaff and Sutton.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Roger B. Sutton, Department of Cell Physiology and Molecular Biophysics, Texas Tech University Health Sciences Center, 3601 4th St., Mailstop 6551, Lubbock, TX 79430-6551, USA e-mail: roger.b.sutton@ttuhsc.edu
This article was submitted to Plant Physiology, a section of the journal Frontiers in Plant Science.
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.